Read Summary

  1. Dorothy A. Shead, MS28,*
  1. From 1Mayo Clinic Cancer Center; 2University of Wisconsin Carbone Cancer Center; 3Moffitt Cancer Center; 4Huntsman Cancer Institute at the University of Utah; 5University of Michigan Comprehensive Cancer Center; 6Dana-Farber/Brigham and Women’s Cancer Center; 7St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; 8UC San Diego Moores Cancer Center; 9Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; 10Fox Chase Cancer Center; 11University of Alabama at Birmingham Comprehensive Cancer Center; 12The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute; 13Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; 14Fred & Pamela Buffett Cancer Center University of Nebraska Medical Center; 15The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 16Duke Cancer Institute; 17Vanderbilt-Ingram Cancer Center; 18Stanford Cancer Institute; 19UCSF Helen Diller Family Comprehensive Cancer Center; 20Roswell Park Cancer Institute; 21Patient Advocate; 22Massachusetts General Hospital Cancer Center; 23Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 24City of Hope Comprehensive Cancer Center; 25Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 26The University of Texas MD Anderson Cancer Center; 27Memorial Sloan Kettering Cancer Center; and 28National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, evaluation, treatment, including supportive-care, and follow-up for patients with myeloma. These NCCN Guidelines Insights highlight the important updates/changes specific to the myeloma therapy options in the 2018 version of the NCCN Guidelines.

Footnotes

  • * Provided content development and/or authorship assistance.

  • Please Note

    The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines® Insights highlight important changes to the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further the understanding of these changes by summarizing salient portions of the NCCN Guideline Panel discussion, including the literature reviewed.

    These NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

    The full and most current version of these NCCN Guidelines are available at NCCN.org.

    © National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

  • Disclosure of Relevant Financial Relationships

    The NCCN staff listed below discloses no relevant financial relationships:

    Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.

    Individuals Who Provided Content Development and/or Authorship Assistance:

    Shaji K. Kumar, MD, Panel Chair, has disclosed that he is a scientific advisor for Amgen, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceutica Products, LP; GlycoMimetics; Sanofi-Aventis U.S.; and Takeda Pharmaceuticals North America, Inc. He receives grant/research support from Abbott Laboratories; Amgen Inc.; Celgene Corporation; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; sanofiaventis U.S.; and Takeda Pharmaceuticals North America, Inc. He also receives consulting fees/honoraria from Kesios Therapeutics; NOXXON Pharma AG; and SkylineDx.

    Natalie S. Callander, MD, Vice Chair, has disclosed that she has no relevant financial relationships.

    Caitlin Costello, MD, Panel Member, has disclosed that she has no relevant financial relationships.

    Craig Hofmeister, MD, MPH, Panel Member, has disclosed that he serves as a scientific advisor for Celgene Corporation. He also receives grant/research support from Celgene Corporation; Janssen Pharmaceutica Products, LP; and Takeda Pharmaceuticals North America, Inc.

    Adetola Kassim, MD, MS, Panel Member, has disclosed that he has no relevant financial relationships.

    Michaela Liedtke, MD, Panel Member, has disclosed that she receives grant/research support and consulting fees/honoraria from Prothena Corporation; Pfizer, Inc.; and Amgen, Inc. She also receives consulting fees/honoraria from Caelum Biosciences, Inc., and receives grant/research support from Takeda Pharmaceuticals North America, Inc.; Celgene Corporation; BlueBirdbio; Gilead Sciences, Inc.; Genetech, Inc.; and Roche Laboratories, Inc.

    Thomas Martin, MD, Panel Member, has disclosed that he receives grant/research support from Amgen Inc.; sanofi-aventis U.S.; and Genzyme Corporation.

    James Omel, MD, Panel Member, has disclosed that he has no relevant financial relationships.

    Dorothy A. Shead, MS, Director, Patient Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

    This activity is supported by educational grants from AstraZeneca, Celldex Therapeutics, Celgene Corporation, Genentech, Jazz Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc. This activity is supported by independent educational grants from AbbVie, Merck & Co., Inc. and NOVOCURE.

Print Friendly, PDF & Email